Tactile Systems Technology, Inc. filings document a Nasdaq-listed medical technology issuer with common stock registered under the ticker TCMD. Recent Form 8-K reports disclose quarterly and annual operating results, financial condition updates, acquisition-related Regulation FD materials, FDA and product-related business highlights, share repurchase authorization activity and other corporate events.
The company's proxy and governance filings cover board composition, director elections, committee assignments, executive compensation, shareholder voting matters and amendments to its certificate of incorporation. Its SEC disclosures also identify Delaware incorporation, Nasdaq listing status, capital actions and governance provisions relevant to its public-company structure.
Morgan Stanley and Morgan Stanley Capital Services LLC have disclosed significant passive stakes in Tactile Systems Technology Inc. common stock. As of 12/31/2025, Morgan Stanley reports beneficial ownership of 1,293,289 shares, representing 5.8% of the class, with all voting and dispositive power shared.
Morgan Stanley Capital Services LLC reports beneficial ownership of 1,154,700 shares, or 5.2% of the class, also with shared voting and dispositive power. The firms certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of Tactile Systems Technology Inc common stock. Dimensional is reported as having beneficial ownership of 1,095,235 shares, representing 4.9% of the outstanding common stock as of the event date of 12/31/2025. It has sole voting power over 1,069,882 shares and sole dispositive power over 1,095,235 shares.
The shares are owned by various funds and accounts that Dimensional advises or manages, and Dimensional disclaims beneficial ownership beyond what is required for Section 13(d) reporting. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Tactile Systems Technology Inc.
Tactile Systems Technology’s Senior Vice President of Marketing & Clinical Affairs, Kristie Burns, reported a planned sale of company stock. On January 2, 2026, she sold 5,139 shares of common stock at a price of $28.85 per share under transaction code “S,” which indicates a sale. After this trade, she beneficially owned 72,401 shares of Tactile Systems Technology common stock in direct ownership.
The sale was made pursuant to a Rule 10b5-1(c) trading plan, which the disclosure notes was adopted on September 11, 2025. Such plans allow insiders to prearrange trades of company stock according to preset instructions, helping separate personal trading decisions from access to inside information.
Tactile Systems Technology, Inc. reported higher revenue and profits in its quarterly report for the period ended September 30, 2025. Revenue rose to $85.8 million, up from $73.1 million a year earlier, driven by both lymphedema and airway clearance products. Airway clearance revenue grew strongly to $13.4 million, while lymphedema products contributed $72.4 million. Gross margin improved to 76% as revenue outpaced cost growth.
Net income increased to $8.2 million versus $5.2 million a year ago, with diluted earnings per share of $0.36. For the first nine months of 2025, revenue reached $225.9 million and net income was $8.5 million. Operating cash flow was strong at $25.5 million, supporting capital spending and shareholder returns.
The company ended the quarter with $66.0 million in cash and no outstanding borrowings under its revised credit facility, after paying off a term loan earlier in the year. It completed a $30.0 million share repurchase program, retiring about 2.34 million shares, and later authorized a new $25.0 million repurchase program extending to November 3, 2027. Shares outstanding were 22.3 million as of September 30, 2025.
Tactile Systems Technology, Inc. (TCMD) announced a new share repurchase program authorizing the company to buy back up to $25 million of its common stock. Repurchases may occur in the open market or through privately negotiated transactions. The program became effective on November 3, 2025 and expires on November 3, 2027.
The company stated it currently expects to fund the program with existing cash and future cash flows. TCMD also furnished a press release disclosing results of operations and financial condition for its most recently completed fiscal quarter as Exhibit 99.1, which, under applicable rules, is not deemed filed.
On 08/08/2025 Sheri Louise Dodd, a director and the Chief Executive Officer of Tactile Systems Technology, sold 7,762 shares of the company’s common stock at $12.356 per share. The Form 4 states the shares were sold to cover taxes associated with the settlement of restricted stock units.
Following the reported sale, Ms. Dodd beneficially owns 173,479 shares, held directly. The disclosure is a routine RSU tax-withholding sale and the form does not report any additional purchases, option exercises, or other material changes to her ownership.
Tactile Systems Technology, Inc. (TCMD) submitted a Form 144 reporting a proposed sale of 7,762 common shares with an aggregate market value of $95,905.72. The filing names Fidelity Brokerage Services LLC as the broker and lists 22,292,145 shares outstanding. The approximate sale date is 08/08/2025 and the securities are listed on NASDAQ. The reported acquisition occurred on 08/07/2025 and is described as Restricted Stock Vesting, with payment characterized as Compensation. The form indicates Nothing to Report for securities sold in the past three months and was submitted as a LIVE filing. The signature section includes the required representation about lack of undisclosed material information.
Cadian Capital Management, LP, its general partner Cadian Capital Management GP, LLC, and managing member Eric Bannasch filed Amendment No. 2 to Schedule 13G on Tactile Systems Technology, Inc. (NASDAQ: TCMD).
- Current position: 2,192,823 common shares as of 7 Aug 2025, representing 9.8 % of outstanding stock (22,292,145 shares outstanding).
- Prior position: 2,309,616 shares (10.4 %) as of 30 Jun 2025. The filing therefore discloses a net reduction of 116,793 shares and a drop below the 10 % reporting threshold.
- All shares are held by Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP. The adviser exercises shared voting and dispositive power; no sole power is reported.
- The securities are held in the ordinary course; the group affirms no intent to influence control of the issuer.
The amendment signals that a major institutional holder remains the company’s largest known shareholder but has modestly trimmed its passive stake.